Yoshinami Tetsuhiro, Yagi Toshinari, Sakai Daisuke, Sugimoto Naotoshi, Imamura Fumio
Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
Intern Med. 2011;50(9):1075-9. doi: 10.2169/internalmedicine.50.4855. Epub 2011 May 1.
A 61-year-old woman with metastatic breast cancer was diagnosed as having acquired Fanconi syndrome. In this case, the cause of this syndrome was most likely zoledronic acid (Zometa), which had been infused intravenously at a dose of 4 mg over 15 minutes weekly because of malignancy-associated hypercalcemia. Zoledronic acid is nephrotoxic and may induce severe tubular dysfunction, which can cause development of Fanconi syndrome. Therefore, close monitoring of proximal tubular function is recommended during therapy with zoledronic acid, especially when frequent administration of zoledronic acid is needed.
一名61岁的转移性乳腺癌女性被诊断为获得性范科尼综合征。在该病例中，该综合征的病因很可能是唑来膦酸（择泰），由于恶性肿瘤相关的高钙血症，她每周静脉输注4毫克唑来膦酸，持续15分钟。唑来膦酸具有肾毒性，可能导致严重的肾小管功能障碍，进而引发范科尼综合征。因此，在使用唑来膦酸治疗期间，建议密切监测近端肾小管功能，尤其是在需要频繁使用唑来膦酸时。
